Clinical Trials Logo
  1. Home
  2. Myeloproliferative Neoplasms
  3. NCT02823210

Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders — CTIM3  

Myeloproliferative Neoplasms Clinical Trial

Official title:
Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Neoplasms (CTIM3)

Clinical Trial Summary

Myeloproliferative neoplasms (MPN) are clonal hematopoietic disorders sharing a common natural evolution: a chronic phase, characterized by a major risk of vascular events, followed by an accelerated phase eventually leading to transformation to acute leukemia. MPN include polycythemia vera, essential thrombocythemia, primary myelofibrosis, and rarer entities. During the past years, CML became a paradigm for targeted therapy and personalized cancer medicine. For other MPNs, the discovery of the JAK2V617F mutation followed by many other mutations, opened similar perspectives. However, several questions remain to be answered in MPNs regarding the clinical implication of these major scientific discoveries: what is the clinical impact of JAK2V617F and other molecular biomarkers on the risks of complications and progression? Can these new biomarkers be used in the perspective of a personalized therapy of MPNs? his project will focus on the qualification of a series of known mutations as biomarkers in MPNs based on large multicenter cohorts of patients with well-annotated samples

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02823210
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Recruiting
Phase
Start date June 2016
Completion date June 2019
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Recruiting NCT05936359 - A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms Phase 1
Completed NCT02084563 - Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms Phase 2
Recruiting NCT04339400 - A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms Phase 1
Completed NCT02125318 - A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders Phase 2
Not yet recruiting NCT06291987 - Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation Phase 1
Recruiting NCT03314974 - Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Phase 2
Completed NCT03075826 - A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms Phase 2
Not yet recruiting NCT06313593 - A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms Phase 1
Active, not recruiting NCT05444530 - A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms Phase 1
Active, not recruiting NCT03912064 - A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Phase 1
Terminated NCT02393248 - Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Phase 1/Phase 2
Completed NCT02076191 - Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Phase 1/Phase 2
Active, not recruiting NCT04761770 - Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders Phase 2
Recruiting NCT06034002 - A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms Phase 1
Completed NCT00949364 - Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage Phase 2
Completed NCT00053196 - Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer Phase 2
Terminated NCT01668173 - HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET Phase 2
Active, not recruiting NCT03618485 - Registry of Patients With MPNs in Taiwan